- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Seth Ginsberg: Biologics and Prior Authorization
Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation, discusses the impact of prior authorization requirements on patients and providers.
Transcript:
How do prior authorizations affect patients who have been prescribed biologics?
Like “fail first,” prior authorization is a tactic used by health insurance providers to reduce prescription drug costs. They serve an important purpose in seeking to reduce healthcare costs; however, when they are excessive in length and difficult to navigate because of variance, and depending on the insurance company requirements, prior authorization can become a real barrier to care.
By requiring physicians to submit additional paperwork to prove that a patient requires an advanced therapy—sometimes still requiring the use of a fax machine—they are encouraging physicians to prescribe an older, possibly less effective option to avoid the prior authorization effort required by the insurer. Physicians often report having to dedicate several staff members full time to processing prior authorization forms for patients. And from the patient perspective, prior authorization requirements mean that accessing their prescription is delayed, which can lead to serious health consequences or complications, not to mention much more stress.
Legislative efforts to address this issue have focused on streamlining and bringing uniformity to prior authorization forms and appeals processes within states around the country.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
IGBA 2023: Dr Monique Mansoura Highlights the Intersection of Geopolitical Issues, Biopharma
February 19th 2023COVID-19 allowed governments to critically examine the biopharma space to increase access to vaccines, but there's still a way to go, according to Monique Mansoura, PhD, MBA, executive director of global health security and biotechnology at the MITRE Corporation, at the International Generic and Biosimilar Medicines Association’s annual meeting.
